PER® New York Lung Cancer Symposium | Conference

Dr. Saxena on a Challenging Case of NSCLC

November 8th 2021

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Dr. Zauderer on the Importance of Optimizing Care in Mesothelioma

November 8th 2021

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC

November 8th 2021

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

KRAS G12C Inhibitors Enter the Spotlight in NSCLC

November 8th 2021

The era of direct inhibitors to treat KRAS G12C-mutated non-small cell lung cancer has arrived in the clinic.

Future of Lung Cancer Treatment Looks Bright With Emerging Technologies, Novel Discoveries

November 8th 2021

Mark G. Kris, MD, discusses recent progress in non–small cell lung cancer and small cell lung cancer, efforts being made to address unmet needs in these paradigms, and ongoing research that is generating excitement.

Examining New Approaches to Management of Immune-Related AEs in Lung Cancer

November 6th 2021

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Timing of Immunotherapy Stoppage in Lung Cancer Varies Depending on Progression, AEs, and Cure

November 6th 2021

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

November 6th 2021

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Dr. Seetharamu on Utilizing a Patient-Centered Treatment Approach in Lung Cancer

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

Dr. Zauderer on Emerging Treatment Strategies in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

Research With Cellular Therapy Ramps Up in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

Clinical Trials Needed to Determine the Utility of Targeted Therapies in Oncogene-Driven Locally Advanced NSCLC

November 5th 2021

Julie Renee Brahmer, MD, MSc, discusses remaining questions regarding immunotherapy and targeted therapy in locally advanced NSCLC, data from the phase 3 PACIFIC and ADAURA trials, and her hopes for future clinical trials in the paradigm.

Chemoimmunotherapy Remains Best Choice for Some PD-L1–High Lung Cancers

November 10th 2020

November 10, 2020 - Nasser Hanna, MD, discusses immunotherapy and, although, it may be the right therapy for most patients with lung cancer expressing PD-L1 greater than or equal to 50%, for those who are at risk for cancer-related morbidity with early progressive disease, chemoimmunotherapy may be the more appropriate choice.

MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer

November 9th 2020

Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.

KRAS G12C Emerges as an Actionable Alteration in NSCLC

November 9th 2020

Although historically considered to be undruggable, the KRAS G12C mutation has since emerged as an actionable alteration in the field of non–small cell lung cancer.

ctDNA Shows Promise as a Potential Biomarker for MRD in Locally Advanced NSCLC

November 9th 2020

Maximilian Diehn, MD, PhD, discusses how the use of circulating tumor DNA to analyze minimal residual disease status in patients with lung cancer and other solid tumors is a rapidly developing field with the potential to further personalize treatment decisions about adjuvant therapy.

Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer

November 9th 2020

The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.